
Peter Ellmark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5595937/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo. Cancer Immunology, Immunotherapy, 2021, 70, 3629-3642.	4.2	11
2	Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy, 2021, 21, 1635-1646.	3.1	15
3	Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. Oncolmmunology, 2020, 9, 1730538.	4.6	23
4	858â€A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies. , 2020, 8, A911-A911.		2
5	Firstâ€inâ€human study with intratumoral administration of a CD40 agonistic antibody, ADCâ€1013, in advanced solid malignancies. International Journal of Cancer, 2019, 145, 1189-1199.	5.1	64
6	The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. , 2019, 7, 103.		79
7	Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunology, Immunotherapy, 2018, 67, 47-60.	4.2	29
8	Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunology, Immunotherapy, 2017, 66, 1-7.	4.2	33
9	Selective Fcl ³ R engagement by human agonistic anti-CD40 antibodies. Translational Cancer Research, 2016, 5, S839-S841.	1.0	1
10	The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity. Clinical Cancer Research, 2015, 21, 1115-1126.	7.0	79
11	Kick-starting the cancer-immunity cycle by targeting CD40. Oncolmmunology, 2015, 4, e1011484.	4.6	14
12	Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncolmmunology, 2014, 3, e27614.	4.6	70
13	Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer. Cancer Immunology Research, 2014, 2, 80-90.	3.4	78
14	Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(1 ³ -glutamic acid) nanoparticles. Biomaterials, 2012, 33, 6230-6239.	11.4	23
15	Identification of a Strongly Activating Human Anti-CD40 Antibody That Suppresses HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2008, 24, 367-373.	1.1	7
16	Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library. Immunology, 2002, 106, 456-463.	4.4	17